- Predictive Oncology Reports First Quarter 2024 Financial Results and Provides Business Update
- Predictive Oncology to Report First Quarter 2024 Financial Results on Wednesday, May 15, 2024
- Predictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu Vaccine
- Predictive Oncology Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update
- Predictive Oncology to Participate in Upcoming Investor Conferences
- Predictive Oncology to Participate in Upcoming San Francisco Conferences
- Predictive Oncology Reports Third Quarter 2023 Financial Results and Provides Business Update
- Predictive Oncology Completes AI-driven Study of Ovarian Cancer with UPMC Magee-Womens Hospital
- Predictive Oncology to Report Third Quarter 2023 Financial Results and Host Conference Call and Webcast on Tuesday, November 14, 2023
More ▼
Key statistics
On Thursday, Predictive Oncology Inc (POAI:NAQ) closed at 1.62, 44.55% above the 52 week low of 1.12 set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.61 |
---|---|
High | 1.64 |
Low | 1.56 |
Bid | 1.31 |
Offer | 1.83 |
Previous close | 1.62 |
Average volume | 55.79k |
---|---|
Shares outstanding | 4.10m |
Free float | 3.96m |
P/E (TTM) | -- |
Market cap | 6.64m USD |
EPS (TTM) | -3.66 USD |
Data delayed at least 15 minutes, as of May 23 2024 20:59 BST.
More ▼